 ObsEva SA OBSV SIX:OBSN, a biopharmaceutical company developing and commercializing novel therapies to improve womens reproductive health, today reported publication in the journal Fertility and Sterility of Gonadotropin-releasing Hormone Antagonist linzagolix: a New Therapy for Uterine Adenomyosis, a case report from a pilot study assessing the use of linzagolix for the treatment of uterine adenomyosis. Adenomyosis is an estrogen-driven condition in which endometrial tissue inner uterine lining is present within the myometrium muscular uterine wall, resulting in uterine enlargement, heavy menstrual bleeding, dysmenorrhea painful menses and infertility. Adenomyosis affects between 20 and 35 of reproductive-aged women, and may co-exist with endometriosis andor uterine fibroids. 